Evidence map›Paper›PMID 37873358›Full record

ArticlebioRxiv : the preprint server for biology2023

Exploration of the Tunability of BRD4 Degradation by DCAF16

Muhammad Murtaza Hassan, Yen-Der Li, Michelle W Ma, Mingxing Teng, Woong Sub Byun, Kedar Puvar, Ryan Lumpkin, Brittany Sandoval, Justine C Rutter, Cyrus Y Jin and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Muhammad Murtaza HassanDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA.
Yen-Der LiDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA.
Michelle W MaDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA.
Mingxing TengCenter for Drug Discovery, Department of Pathology & Immunology, and Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX.
Woong Sub ByunDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA.
Kedar PuvarDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Ryan LumpkinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Brittany SandovalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Justine C RutterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Cyrus Y JinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Michelle Y WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Shawn XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Anna M SchmokerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Hakyung CheongDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA.
Brian J GroendykeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Jun QiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Nathanael S GrayDepartment of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA.
Harvard University · USDana-Farber Cancer Institute · USBroad Institute · USStanford University · USBaylor College of Medicine · US

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6M
Functional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8M
The role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9M
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACsR01CA262188 · NCI · DANA-FARBER CANCER INST · PI FISCHER, ERIC SEBASTIAN · 2022 to 2025
$1.8M
500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709k
NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA262188NCI NIH HHS R35 CA253125NHLBI NIH HHS R01 HL082945NIH HHS S10 OD028697
6 · The paper itself

Abstract

Small molecules that can induce protein degradation by inducing proximity between a desired target and an E3 ligase have the potential to greatly expand the number of proteins that can be manipulated pharmacologically. Current strategies for targeted protein degradation are mostly limited in their target scope to proteins with preexisting ligands. Alternate modalities such as molecular glues, as exemplified by the glutarimide class of ligands for the CUL4

Identifiers

PMID37873358
PMCPMC10592706
OpenAlexW4387487458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.